IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.120
-0.030 (-2.61%)
At close: Dec 20, 2024, 4:00 PM
1.110
-0.010 (-0.89%)
After-hours: Dec 20, 2024, 5:55 PM EST
IceCure Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for IceCure Medical stock have an average target of 2.70, with a low estimate of 2.50 and a high estimate of 2.90. The average target predicts an increase of 141.07% from the current stock price of 1.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ICCM stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +123.21% | Nov 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +123.21% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2.5 | Strong Buy | Reiterates | $2.5 | +123.21% | Sep 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $2.5 | Strong Buy | Maintains | $3 → $2.5 | +123.21% | Aug 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +167.86% | Jul 2, 2024 |
Financial Forecast
Revenue This Year
3.83M
from 3.23M
Increased by 18.61%
Revenue Next Year
5.93M
from 3.83M
Increased by 54.91%
EPS This Year
-0.29
from -0.32
EPS Next Year
-0.26
from -0.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.0M | 6.1M | 35.6M | |||
| Avg | 3.8M | 5.9M | 34.5M | |||
| Low | 3.6M | 5.7M | 33.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 25.4% | 60.4% | 499.4% | |||
| Avg | 18.6% | 54.9% | 482.3% | |||
| Low | 10.9% | 48.0% | 459.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.29 | -0.26 | - | |||
| Avg | -0.29 | -0.26 | - | |||
| Low | -0.28 | -0.25 | - |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.